In the critical area of cancer care, healthcare providers are experiencing a growing pressure to improve patient safety and decrease operators’ risk, while increasing efficiently and containing costs.
The compounding of patient-specific chemotherapies in the hospital environment is a particularly challenging area, due to the following main factors:
- high potential for adverse drug events, because of dosing inaccuracies related to the manual compounding process
- possible medication errors, related to the incidental exchange of drugs or final containers
- significant occupational risk for the clinical staff, due to the high toxicity of drugs to be manipulated
- increasing cost of high specificity oncologic drugs
What is ChemoMaker+?
ChemoMaker+ is an innovative technology for the compounding of patient-specific chemotherapy drugs, solving the most of critical issues related to the manual preparation process usually adopted in hospitals.
ChemoMaker+ directly addresses these challenges in order to:
- increase patient safety
- lower operators’ risk of contamination
- reduce operating costs optimizing the use of drugs
- increasing accuracy.
ChemoMaker+ is a compact system, that can be easily placed in an existing Class II laminar flow hood. It does not require dedicated spaces or installation works.
The system is based on a robotic unit, able to fully automatize the dosing process (i.e.: the transfer of drugs from vials to infusion bags). Patient doses, ready to be administered, are prepared in a sterile environment, and the compounding robot, is placed under a sterile laminar flow hood. A closed system prevents the contamination of the environment by toxic drugs.
The proper formulation is guaranteed by a real-time gravimetric control system able to ensure dosage accuracies up to 0.1%, more than one order of magnitude higher than the precision allowed by the European Pharmacopoeia in manual preparations.
ChemoMaker+ is wireless connected to a computer, which allows the operators of the hospital pharmacy to organize the preparation activity according to the prescriptions received from the oncology departments. All materials are identified by barcodes and RFID tags for maximum safety. Multiple automatic checks assure high accuracy and safety of the final product.
The drug is dosed directly into the final containers intended for administration (bags, syringes, elastomeric pumps), in order to avoid any subsequent manipulation, preventing contamination for healthcare professionals and patients.
Drugs and final containers are selected according to prescriptions
Drugs are identified by a double-check system: barcode and RFID
Infusion bags are associated to each patient-specific therapy
Drug vials and infusion bags are loaded on the compounder
ChemoMaker+ automatically compounds all medications
Identification labels containing all preparation data and barcode are automatically printed for each dose.
Advantages vs. manual compounding
Automated check and verification of the whole compounding cycle
No contamination risks for the pharmacy operators
High dosing accuracy, individually verified for each compounded dose
Human errors prevention, less risks for patients
Optimization of unused drugs waste, significant cost saving
Biovalley Investments SpA (today Biovalley Group SpA) is set as a “Family and Friends Office” and manages the investments made in companies of the BioHighTech sector as biomedical, biotechnologies and bioinformatics. The main activity is in order to accelerate the development and asset value of this high specialized sector.Visit Website
You can contact us by phone at +39 040 899 2219 or through our email. We’ll get back to you as soon as we can.
Via Flavia 23/1 34148 c/o BIC Incubatori FVG, Trieste, Italy
+39 040 899 2219